Tevogen (TVGN) Share-based Compensation (2022 - 2026)
Tevogen's (TVGN) quarterly Share-based Compensation came in at $2.8 million in Q1 2026, down 60.93% on a YoY basis from $7.3 million in Q1 2025, and up 16.5% quarter-over-quarter from $2.4 million in Q4 2025.
Analysis
Tevogen (TVGN) Share-based Compensation (2022 - 2026) Analysis & Trends
Tevogen (TVGN) has reported Share-based Compensation for 5 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 60.93% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $19.5 million (down 51.47% YoY), and the FY2025 full-year result was $83.9 million, up 105.7% from the prior year.
- Share-based Compensation climbed to $2.8 million in Q1 2026 per TVGN's latest filing, from $2.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $86.1 million in Q3 2025 and bottomed at -$302399.0 in Q4 2023.
- Historically, Share-based Compensation has averaged $17.7 million across 5 years, with a median of $8.6 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation sank 103.06% in 2023, then surged 123475.42% in 2024.
- Over 5 years, Share-based Compensation stood at $9.9 million in 2022, then tumbled by 103.06% to -$302399.0 in 2023, then soared by 2401.93% to $7.0 million in 2024, then sank by 64.86% to $2.4 million in 2025, then rose by 16.5% to $2.8 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.8 million, $2.4 million, and $86.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 14.16 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 17.32 Mn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 17.57 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 17.40 Mn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 40.78 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 90.90 Mn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 3.58 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 28.03 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 9.08 Mn |
| 10 | Tevogen | 27.76 Mn | 27.76 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 2.85 Mn |
| Dec 31, 2025 | 2.45 Mn |
| Sep 30, 2025 | 86.09 Mn |
| Jun 30, 2025 | 31.08 Mn |
| Mar 31, 2025 | 7.29 Mn |
| Dec 31, 2024 | 6.96 Mn |
| Sep 30, 2024 | 20.23 Mn |
| Jun 30, 2024 | 19.35 Mn |
| Mar 31, 2024 | 26.33 Mn |
| Dec 31, 2023 | -302,399.00 |
| Mar 31, 2023 | -21,344.00 |
| Dec 31, 2022 | 9.89 Mn |